Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 11;28(7):taab119.
doi: 10.1093/jtm/taab119.

Neutralization of Delta variant with sera of Covishield™ vaccinees and COVID-19-recovered vaccinated individuals

Gajanan N Sapkal  1 , Pragya D Yadav  1 , Rima R Sahay  1 , Gururaj Deshpande  1 , Nivedita Gupta  2 , Dimpal A Nyayanit  1 , Deepak Y Patil  1 , Anita M Shete  1 , Sanjay Kumar  3 , Priya Abraham  1 , Samiran Panda  2 , Balram Bhargava  2
Affiliations

Neutralization of Delta variant with sera of Covishield™ vaccinees and COVID-19-recovered vaccinated individuals

Gajanan N Sapkal et al. J Travel Med. .
No abstract available

Keywords: AZD1222; Adenoviral-vector vaccines; AstraZeneca; ChAdOx-1; vaccine effectiveness; variants of concern.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Neutralization antibody titer of individual sera from different categories against SARS-CoV-2 B.1 (D614G) and Delta (B.1.617.2) strains and RBD-S1 and N protein titer: NAb titer against the B.1 (pink) and Delta (green) was compared between participants administered with one dose Covishield™ vaccine (A), two doses of vaccine (B), COVID-19-recovered individuals administered with one dose Covishield™ vaccine (C), COVID-19-recovered individuals administered with two doses (D) and breakthrough participant (E); a two-tailed pair-wise comparison was performed using the Wilcoxon matched-pairs signed-rank test to analyze the statistical significance; comparison of NAb titer between participants administered with one dose Covishield™ vaccine (red color), two doses of Covishield™ vaccine (green color), Covishield™ vaccine to COVID-19-recovered individuals administered with one dose (purple color) and two doses (orange color) and breakthrough (blue color) participants against B.1 strain (F) and Delta strain (G); IgG titers of participant’s sera from different categories for SARS-CoV-2 RBD protein (H) and N protein ELISA (I); the statistical significance was assessed using two-tailed Kruskal Wallis test with Dunn’s test of multiple comparisons to analyze the statistical significance, and a P value less than 0.05 was considered to be statistically significant; the dotted line on the figures indicates the limit of detection of the assay; data are presented as mean values +/− standard deviation (SD).
See this image and copyright information in PMC

Comment in

References

    1. PANGO lineages . https://cov-lineages.org/lineages/lineage_B.1.617.html26 June 2021, date last accessed.
    1. World Health Organization. COVID-19 Vaccine Tracker and Landscape. https://www. who.int/publications/m/item/draft-landscape-of-covid-19-can...26 June 2021, date last accessed.
    1. Thevarajan I, Nguyen THO, Koutsakos Met al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med 2020; 26:453–5. - PMC - PubMed
    1. Creech CB, Walker SC, Samuels RJ. SARS-CoV-2 vaccines. JAMA 2021; 325:1318–20. - PubMed
    1. Hacisuleyman E, Hale C, Saito Yet al. Vaccine breakthrough infections with SARS-CoV-2 variants. New Eng J Med 2021; 384:2212–8. - PMC - PubMed

Publication types

Substances